NEW YORK (GenomeWeb) – Synthetic biology startup Synlogic today announced it has raised $29.4 million in Series A financing.

Atlas Ventures and New Enterprise Associates led the round. Cambridge, Mass.-based Synlogic plans to use proceeds from the raise to further develop its microbial engineering platform for developing therapeutic microbes and advancing its preclinical pipeline across clinical applications, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.